Clinical Case Reports (Sep 2021)
Programmed cell death ligand 1 expression in a case of poorly differentiated lymphocyte‐rich hepatocellular carcinoma
- Ginji Omori,
- Takahiro Osuga,
- Koji Miyanishi,
- Kota Hamaguchi,
- Shingo Tanaka,
- Hiroyuki Ohnuma,
- Kazuyuki Murase,
- Kohichi Takada,
- Minoru Nagayama,
- Yasutoshi Kimura,
- Ichiro Takemasa,
- Yasuhiro Kikuchi,
- Toshihiko Torigoe,
- Junji Kato
Affiliations
- Ginji Omori
- Department of Medical Oncology Sapporo Medical University School of Medicine Sapporo Japan
- Takahiro Osuga
- Department of Medical Oncology Sapporo Medical University School of Medicine Sapporo Japan
- Koji Miyanishi
- Department of Medical Oncology Sapporo Medical University School of Medicine Sapporo Japan
- Kota Hamaguchi
- Department of Medical Oncology Sapporo Medical University School of Medicine Sapporo Japan
- Shingo Tanaka
- Department of Medical Oncology Sapporo Medical University School of Medicine Sapporo Japan
- Hiroyuki Ohnuma
- Department of Medical Oncology Sapporo Medical University School of Medicine Sapporo Japan
- Kazuyuki Murase
- Department of Medical Oncology Sapporo Medical University School of Medicine Sapporo Japan
- Kohichi Takada
- Department of Medical Oncology Sapporo Medical University School of Medicine Sapporo Japan
- Minoru Nagayama
- Department of Surgery, Surgical Oncology and Science Sapporo Medical University School of Medicine Sapporo Japan
- Yasutoshi Kimura
- Department of Surgery, Surgical Oncology and Science Sapporo Medical University School of Medicine Sapporo Japan
- Ichiro Takemasa
- Department of Surgery, Surgical Oncology and Science Sapporo Medical University School of Medicine Sapporo Japan
- Yasuhiro Kikuchi
- Department of Pathology Sapporo Medical University School of Medicine Sapporo Japan
- Toshihiko Torigoe
- Department of Pathology Sapporo Medical University School of Medicine Sapporo Japan
- Junji Kato
- Department of Medical Oncology Sapporo Medical University School of Medicine Sapporo Japan
- DOI
- https://doi.org/10.1002/ccr3.4764
- Journal volume & issue
-
Vol. 9,
no. 9
pp. n/a – n/a
Abstract
Abstract Our pathological study of a case of poorly differentiated lymphocyte‐rich hepatocellular carcinoma suggested that immune checkpoint inhibitor may be an effective therapy. The histological type is an important factor in determining treatment choices.
Keywords
- hepatocellular carcinoma
- immune checkpoint inhibitors
- lymphocyte‐rich
- lymphoepithelial hepatocellular carcinoma
- programmed cell death ligand 1
